BMS IDHENTIFY trial of Idhifa misses primary goal in AML patients
BMS’ Phase III trial of Idhifa misses primary endpoint in AML. Credit: A 4.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more